

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 28, 2003, 18:21:02 ; Search time 37.0909 Seconds
(without alignments)
51.353 Million cell updates/sec

Title: US-09-743-225-8
Perfect score: 58
Sequence: 1 NTLKTPRVGGXA.12

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Result No.	Score	Query Match	Length	ID	Description
1	56	96.6	12	21 AAY69259	Monopeptide which
2	53	91.4	10	21 AAY69268	Peptide which inh
3	53	91.4	11	21 AAB17990	Beta-2GPI Ab bindi
4	53	91.4	11	23 ABB73361	Exemplary pharmaco
5	41	70.7	8	21 AAB17989	Beta-2GPI Ab bindi
6	41	70.7	8	23 ABB73360	Exemplary pharmaco
7	38	65.5	372	24 ABB77111	N. gonorrhoeae ami
8	37	63.8	68	20 AAY11550	Human 5' EST seque
9	37	63.8	82	20 AAY11742	Human 5' EST seque

SUMMARIES

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

10	37	63.8	388	23	ABP66299	Bifidobacterium lo
11	36	62.1	92	22	AAU48931	Propionibacterium
12	36	62.1	140	22	AAM93750	Human polypeptide,
13	36	62.1	256	23	ABE54460	Lactococcus lactis
14	36	62.1	319	21	AG06393	Arabidopsis thalia
15	36	62.1	323	21	AG06392	Arabidopsis thalia
16	36	62.1	330	22	AAU41960	Propionibacterium
17	36	62.1	1002	21	ABE23854	Haemophilus Influe
18	36	62.1	1301	23	ABE77633	Ampev fifth RNA po
19	35	60.3	58	22	AAH84843	Human immune/haema
20	35	60.3	144	22	AAH86368	Human immune/haema
21	35	60.3	200	23	AAH49451	Escherichia coli D
22	35	60.3	234	22	ABG08877	Novel human diagno
23	35	60.3	332	21	AG14804	Arabidopsis thalia
24	35	60.3	332	21	AG48466	Arabidopsis thalia
25	35	60.3	364	14	AAE39215	Mutant PDG encoded
26	35	60.3	365	14	AAE39214	Mutant PDG encoded
27	35	60.3	367	21	AG14803	Arabidopsis thalia
28	35	60.3	367	21	AG48465	Arabidopsis thalia
29	35	60.3	374	14	AAE39221	Mutant PDG encoded
30	35	60.3	395	14	AAE39218	Mutant PDG encoded
31	35	60.3	403	14	AAE39220	Mutant PDG encoded
32	35	60.3	404	14	AAE39222	Mutant PDG encoded
33	35	60.3	405	14	AAE39213	Mutant PDG encoded
34	35	60.3	410	14	AAE39212	Mutant PDG encoded
35	35	60.3	410	15	AAE50093	E. coli phosphogly
36	35	60.3	410	22	AAU34698	Wild-type phosphog
37	35	60.3	411	14	AAE39219	E. coli cellular p
38	35	60.3	412	14	AAE39217	Mutant PDG encoded
39	35	60.3	414	14	AAE39216	Mutant PDG encoded
40	35	60.3	456	21	AAE14802	Arabidopsis thalia
41	35	60.3	456	21	AAE48464	Arabidopsis thalia
42	35	60.3	884	22	ABG22489	Novel human diagno
43	35	60.3	884	22	ABG30084	Novel human diagno
44	35	60.3	1072	22	ABG04157	Novel human diagno
45	34	58.6	84	22	AAO01684	Human polypeptide

ALIGNMENTS

RESULT 1	
AAE69259	standard; peptide; 12 AA.
ID	AAE69259 standard; peptide; 12 AA.
XX	
AC	AAE69259;
XX	
DT	30-MAY-2000 (first entry)
XX	
DE	Monopeptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
XX	
KW	Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;
KW	anti-phospholipid syndrome; anti-phospholipid antibody;
KW	pregnancy complication; thrombosis; coagulation dysregulation.
XX	
OS	Synthetic.
XX	
EH	Key Location/Qualifiers
FT	Modified-site 11
FT	/note= "FmocLys(Fmoc)-OH"
XX	
PN	WO200001729-A2.
XX	
PD	13-JAN-2000.
XX	
PF	06-JUL-1999; 99WO-IL00366.
XX	
PR	07-JUL-1998; 98IL-0125262.
XX	
PA	(YEDA) YEDA RES & DEV CO LTD.
XX	
PI	Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
XX	

DR WPI; 2000-182105/16.

XX Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1

PT antibodies, useful for diagnosis and treatment of anti-phospholipid

PT syndrome in humans

XX

PS Disclosure; Page 13; 58pp; English.

XX

CC The present sequence represents a synthetic peptide which is capable

CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1

CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo

CC induction of experimental anti-phospholipid syndrome in mice by

CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis

CC and treatment of anti-phospholipid syndrome. They may also be used

CC for the diagnosis of anti-phospholipid antibodies with different

CC pathogenic biofunctions which may correlate with either pregnancy

CC complications, thrombosis or coagulation dysregulation.

XX

SQ Sequence 12 AA;

Query Match 96.68; Score 56; DB 21; Length 12;

Best Local Similarity 100.0%; Pred. No. 0.00069;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NTLKTPRVGGXA 12

DB 1 NTLKTPRVGGXA 12

RESULT 2

AAAY69268

ID AAY69268 standard; peptide; 10 AA.

XX

AC AAY69268;

XX

DT 30-MAY-2000 (first entry)

XX

DE Peptide which inhibits anti-beta-2-glycoprotein 1 antibodies.

XX

KW Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;

KW anti-phospholipid syndrome; anti-phospholipid antibody;

KW pregnancy complication; thrombosis; coagulation dysregulation.

XX

OS Synthetic.

XX

PN WO200001729-A2.

XX

PD 13-JAN-2000.

XX

PF 06-JUL-1999; 99WO-IL00366.

XX

PR 07-JUL-1998; 98IL-0125262.

XX

PA (YEDA) YEDA RES & DEV CO LTD.

XX

PI Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;

XX

DR WPI; 2000-182105/16.

XX

PT Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1

PT antibodies, useful for diagnosis and treatment of anti-phospholipid

PT syndrome in humans

XX

PS Claim 3; Page 37; 58pp; English.

XX

CC The present sequence represents a synthetic peptide which is capable

CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1

CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo

CC induction of experimental anti-phospholipid syndrome in mice by

CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis

CC and treatment of anti-phospholipid syndrome. They may also be used

CC for the diagnosis of anti-phospholipid antibodies with different

CC pathogenic biofunctions which may correlate with either pregnancy

CC complications, thrombosis or coagulation dysregulation.

XX

SQ Sequence 10 AA;

Query Match 91.48; Score 53; DB 21; Length 10;

Best Local Similarity 100.0%; Pred. No. 0.0021;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NTLKTPRVGG 10

DB 1 NTLKTPRVGG 10

RESULT 3

AAAB17990

ID AAB17990 standard; Peptide; 11 AA.

XX

AC AAB17990;

XX

DT 31-OCT-2000 (first entry)

XX

DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1102.

XX

KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;

KW autoimmune disease; cystostatic; antiasthmatic; thrombolytic; VEGF;

KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;

KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;

KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;

KW vascular endothelial growth factor; matrix metalloproteinase;

KW asthma; thrombosis; pharmaceutical.

XX

OS Synthetic.

XX

PN WO2000024782-A2.

XX

PD 04-MAY-2000.

XX

PF 25-OCT-1999; 99WO-US25044.

XX

PR 23-OCT-1998; 98US-0105371.

PR 22-OCT-1999; 99US-0428082.

XX

PA (ANGE-) AMGEN INC.

XX

PI Felge U, Liu C, Cheetham J, Boone TC;

XX

DR WPI; 2000-350702/30.

XX

PT Novel composition of matter comprising an Fc domain and

PT pharmacologically active peptides, useful for treating cancer and

PT autoimmune diseases

XX

PS Claim 39; Page 599; 608pp; English.

XX

CC The present invention describes composition of matter (I) comprising an

CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:

CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each

CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,

CC -(L1)c-P1-(L2)d-P2-(L3)e-P3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4

CC where P1, P2, P3, and P4 = are each independently sequences of

CC pharmacologically active peptides; L1, L2, L3, and L4 = are each

CC independently linkers; and a, b, c, d, e, and f = are each independently

CC 0 or 1, provided that at least 1 of a and b is 1. The composition can

CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive

CC activities. DNAs, vectors and host cells from the present invention can

CC be used for producing pharmaceutical compositions. The compositions are

CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.

CC The use of an Fc domain (rather than a Fab domain) can provide a longer

CC half-life or incorporate functions such as Fc receptor binding, protein

CC A binding, complement fixation, and possibly placental transfer. AAG6943

CC to AAG69526 and AAB16955 to AAB18003 represent nucleotide and amino acid

CC sequences used in the exemplification of the present invention.

XX

SQ Sequence 11 AA;
 Query Match 91.4%; Score 53; DB 21; Length 11;
 Best Local Similarity 100.0%; Pred. No. 0.0023;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NTLKTPRVGG 10
 Db 1 NTLKTPRVGG 10
 |||||

RESULT 4
 ABB73361
 ID ABB73361 standard; Peptide; 11 AA.
 XX AC ABB73361;
 XX DT 05-APR-2002 (first entry)
 XX DE Exemplary pharmacologically active peptide SEQ ID NO:1100.

XX KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
 KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
 KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
 KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
 KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
 KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
 KW antianemic; anorectic; antinfertility; haemostatic; dermatological;
 KW neuroprotective; inflammatory arthritis; autoimmune disease; tumour growth;
 KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
 KW sleep disorder; neurological degenerative disease; anaemia;
 KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
 KW Fanconi's syndrome.

XX OS Synthetic.
 XX OS WO200183525-A2.
 XX PN 08-NOV-2001.
 XX PD 02-MAY-2001; 2001WO-US14310.
 XX PF 03-MAY-2000; 2000US-0563286.
 XX PR (AMGE-) AMGEN INC.
 XX PA Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
 XX PI WPI; 2002-130313/17.
 XX DR Novel vehicle-peptide molecule or its multimers useful for treating
 XX PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
 XX PT diabetic retinopathy, obesity, sleep disorders and infertility -
 XX PS Claim 39; Page 62; 176pp; English.

XX CC The present invention describes a vehicle-peptide molecule (I) or its
 CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
 CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
 CC antianemic, anorectic, antinfertility, haemostatic, dermatological and
 CC neuroprotective activities. (I) can be used as a therapeutic or
 CC prophylactic agent as well as for screening purposes. (I) is useful for
 CC diagnosing diseases characterised by dysfunction of their associated
 CC protein of interest, for identifying normal or abnormal proteins of
 CC interest, as a part of diagnostic kit to detect the presence of their
 CC proteins of interest in a biological sample. Additionally, (I) is useful
 CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
 CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
 CC infertility, and neurological degenerative diseases. (I), comprising
 CC EPO-mimetic compounds are useful for treating disorders characterised by
 CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
 CC compounds are useful for treating conditions that involve an existing
 CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet

CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
 CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
 CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABB35695 to ABB35777
 CC represent amino acid and nucleic acid sequences used in the
 CC exemplification of the present invention.

XX SQ Sequence 11 AA;
 Query Match 91.4%; Score 53; DB 23; Length 11;
 Best Local Similarity 100.0%; Pred. No. 0.0023;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NTLKTPRVGG 10
 Db 1 NTLKTPRVGG 10
 |||||

RESULT 5
 AAB17989
 ID AAB17989 standard; Peptide; 8 AA.
 XX AC AAB17989;
 XX DT 31-OCT-2000 (first entry)
 XX DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1101.

XX KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
 KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
 KW immunosuppressive; EPO; TPO; CPLA4; mimetic; IL-1; TNF; antagonist;
 KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
 KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
 KW vascular endothelial growth factor; matrix metalloproteinase;
 KW asthma; thrombosis; pharmaceutical.

XX OS Synthetic.
 XX OS WO200024782-A2.
 XX PN 04-MAY-2000.
 XX PD 25-OCT-1999; 99WO-US25044.
 XX PF 23-OCT-1998; 98US-0105371.
 XX PR 22-OCT-1999; 99US-0428082.
 XX PA (AMGE-) AMGEN INC.
 XX XX Feige U, Liu C, Cheetham J, Boone TC;
 XX PI WPI; 2000-350702/30.
 XX DR Novel composition of matter comprising an Fc domain and
 XX PT pharmacologically active peptides, useful for treating cancer and
 XX PT autoimmune diseases -
 XX PS Claim 39; Page 599; 608pp; English.

XX CC The present invention describes composition of matter (I) comprising an
 CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
 CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
 CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
 CC -(L1)c-P1-(L2)d-P2-(L3)e-P3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
 CC where P1, P2, P3, and P4 = are each independently sequences of
 CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
 CC independently linkers; and a, b, c, d, e, and f = are each independently
 CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
 CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
 CC activities. DNAs, vectors and host cells from the present invention can
 CC be used for producing pharmaceutical compositions. The compositions are
 CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
 CC The use of an Fc domain (rather than a Fab domain) can provide a longer
 CC half-life or incorporate functions such as Fc receptor binding, protein

CC A binding, complement fixation, and possibly placental transfer. AAA69443
 CC to AA69536 and AAB16955 to AAB18003 represent nucleotide and amino acid
 CC sequences used in the exemplification of the present invention.

XX
 SQ Sequence 8 AA;
 Query Match 70.7%; Score 41; DB 21; Length 8;
 Best Local Similarity 100.0%; Pred. No. 9.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NTLKTPRV 8
 |||||
 DB 1 NTLKTPRV 8

RESULT 6
 ABB73360
 ID ABB73360 standard; Peptide; 8 AA.

XX AC ABB73360;

XX 05-APR-2002 (first entry)

XX Exemplary pharmacologically active peptide SEQ ID NO:1099.

XX Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
 KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
 KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TNF;
 KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
 KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
 KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
 KW antianemic; anorectic; antinfertility; haemostatic; dermatological;
 KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
 KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
 KW sleep disorder; neurological degenerative disease; anaemia;
 KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
 KW Fanconi's syndrome.

XX Synthetic.

XX WO200183525-A2.

XX 08-NOV-2001.

XX 02-MAY-2001; 2001WO-US14310.

XX 03-MAY-2000; 2000US-0563286.

XX (AMGE-) AMGEN INC.

XX Felge U, Liu C, Cheetham JC, Boone TC, Gudas JM;

XX WPI; 2002-130313/17.

XX Novel vehicle-peptide molecule or its multimers useful for treating
 PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
 PT diabetic retinopathy, obesity, sleep disorders and infertility

XX Claim 39; Page 62; 176pp; English.

XX The present invention describes a vehicle-peptide molecule (I) or its
 CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
 CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
 CC antianemic, anorectic, antinfertility, haemostatic, dermatological and
 CC neuroprotective activities. (I) can be used as a therapeutic or
 CC prophylactic agent as well as for screening purposes. (I) is useful for
 CC diagnosing diseases characterised by dysfunction of their associated
 CC protein of interest, for identifying normal or abnormal proteins of
 CC interest, as a part of diagnostic kit to detect the presence of their
 CC proteins of interest in a biological sample. Additionally, (I) is useful
 CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
 CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
 CC infertility, and neurological degenerative diseases. (I), comprising

CC EPO-mimetic compounds are useful for treating disorders characterised by
 CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
 CC compounds are useful for treating conditions that involve an existing
 CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
 CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
 CC tumour which result in thrombocytopaenia; systemic lupus erythematosus,
 CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
 CC represent amino acid and nucleic acid sequences used in the
 CC exemplification of the present invention.

XX SQ Sequence 8 AA;

Query Match 70.7%; Score 41; DB 23; Length 8;
 Best Local Similarity 100.0%; Pred. No. 9.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NTLKTPRV 8
 |||||

DB 1 NTLKTPRV 8

RESULT 7
 ABB77111
 ID ABB77111 standard; Protein; 372 AA.

XX AC ABB77111;

XX 07-MAR-2003 (first entry)

XX N. gonorrhoeae amino acid sequence SEQ ID 752.

XX Antibacterial; infection; vaccine; gene therapy.

XX Neisseria gonorrhoeae.

XX WO200279243-A2.

XX 10-OCT-2002.

XX 12-FEB-2002; 2002WO-IB02069.

XX 12-FEB-2001; 2001GB-0003424.

XX (CHIR-) CHIRON SPA.

XX Fontana MR, Pizza M, Maignani V, Monaci E;

XX WPI; 2003-058415/05.

XX N-PSDB; ABZ38081.

XX New protein from Neisseria gonorrhoeae, useful for the manufacture of a
 PT medicament for treating or preventing N. gonorrhoeae infection

XX Disclosure; Page 244; 815pp; English.

XX The present invention relates to proteins from Neisseria gonorrhoeae.
 CC Also disclosed are the nucleic acid molecules encoding the proteins and
 CC antibodies that specifically bind to the proteins. The composition
 CC comprising the protein, nucleic acid or antibody is useful for the
 CC manufacture of a medicament for treating or preventing N. gonorrhoeae
 CC infection, this may be in the form of a vaccine or gene therapy.
 CC Sequences given in records ABB76736-ABP81046 represent nucleic acid
 CC molecules of the invention.

XX SQ Sequence 372 AA;

Query Match 65.5%; Score 38; DB 24; Length 372;
 Best Local Similarity 70.0%; Pred. No. 62;
 Matches 7; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 NTLKTPRVGG 10
 :||: ||||

DB 182 DTLRPRVGG 191

RESULT 8

AA11550
ID AAY11550 standard; Protein; 68 AA.

XX AC AAY11550;
XX DT 16-JUN-1999 (first entry)
XX DE Human 5' EST secreted protein SEQ ID NO: 202.
XX KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX OS Homo sapiens.
XX PN W0906439-A2.
XX PD 11-FEB-1999.
XX PF 31-JUL-1998; 98WO-IB01233.
XX PR 01-AUG-1997; 97US-0904468.
XX PA (GEST) GENSET.
XX PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX DR WPI; 1999-153700/13.
XX DR N-PSDB; AAX40268.
XX PT New nucleic acids encoding human secreted proteins - obtained from
XX PT cDNA libraries derived from liver, lung, large intestine, colon,
XX PT thyroid and pancreas tissue
XX PS Claim 27; Page 318; 398pp; English.

XX CC AAX40251 to AAX40397 represent 5' expressed sequence tags (ESTs) for
XX CC human secreted proteins, and encode the proteins given in AAY11533 to
XX CC AAY11679, respectively. The proteins given represent the signal peptide
XX CC and an N-terminal fragment of a secreted protein. The nucleic acid
XX CC sequences can be used for producing secreted human gene products. They
XX CC can also be used to develop products for diagnosis and therapy. The
XX CC proteins obtained may have cytokine activity, cell
XX CC proliferation/differentiation activity, haematopoiesis regulating
XX CC activity, tissue growth regulating activity, reproductive hormone
XX CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
XX CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
XX CC activity, tumour inhibition activity or other activities. The products
XX CC can be used in forensic, gene therapy and chromosome mapping procedures.
XX CC The sequences can also be used for obtaining corresponding promoter
XX CC sequences. The nucleic acids encoding the signal peptide can be used for
XX CC directing extracellular secretion of a polypeptide or the insertion of a
XX CC polypeptide into a membrane, or importing a polypeptide into a cell.

SQ Sequence 68 AA;

Query Match 63.8%; Score 37; DB 20; Length 68;
Best Local Similarity 63.6%; Pred. No. 17;
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TLKTPRVGGXA 12
||| | : | : | : |
Db 9 TLSTERIGGAA 19

RESULT 9
AAY11742

ID AAY11742 standard; Protein; 82 AA.

XX AC AAY11742;
XX DT 18-JUN-1999 (first entry)
XX DE Human 5' EST secreted protein SEQ ID No: 342.
XX KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX OS Homo sapiens.
XX PN W09906550-A2.
XX PD 11-FEB-1999.
XX PF 31-JUL-1998; 98WO-IB01232.
XX PR 01-AUG-1997; 97US-0905144.
XX PA (GEST) GENSET.
XX PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX DR WPI; 1999-153780/13.
XX DR N-PSDB; AAX40464.
XX PT New isolated prostate-derived nucleic acids - used to develop
XX PT products which may have cytokine, immune regulatory, haematopoiesis
XX PT regulating, anti-inflammatory or tumour inhibition activity
XX PS Claim 34; Page 517-518; 675pp; English.

XX CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
XX CC human secreted proteins expressed in prostate, and encode the proteins
XX CC given in AAY11716 to AAY11993 respectively. The proteins given represent
XX CC the signal peptide and an N-terminal fragment of a secreted protein. The
XX CC nucleic acid sequences can be used for producing secreted human gene
XX CC products. They can also be used to develop products for diagnosis and
XX CC therapy. The proteins obtained may have cytokine activity, cell
XX CC proliferation and differentiation activity, haematopoiesis regulating
XX CC activity, tissue growth regulating activity, reproductive hormone
XX CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
XX CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
XX CC activity, tumour inhibition activity or other activities. The products
XX CC can be used in forensic, gene therapy and chromosome mapping procedures.
XX CC The sequences can also be used for obtaining corresponding promoter
XX CC sequences. The nucleic acids encoding the signal peptides can be used for
XX CC directing extracellular secretion of a polypeptide or the insertion of a
XX CC polypeptide into a membrane, or importing a polypeptide into a cell.

SQ Sequence 82 AA;

Query Match 63.8%; Score 37; DB 20; Length 82;
Best Local Similarity 63.6%; Pred. No. 20;
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 TLKTPRVGGXA 12
||| | : | : | : |
Db 9 TLSTERIGGAA 19

RESULT 10
ABP66299
ID ABP66299 standard; Protein; 388 AA.

XX AC ABP66299;

XX XX

DT 19-NOV-2002 (first entry)
DE Bifidobacterium longum NCC2705 ORF amino acid sequence SEQ ID NO:1043.
XX
DE Bifidobacterium longum NCC2705; Bifidobacterium; bacterial;
XX
KW antidiarrheic; antibacterial; inhibitor of Salmonella; detection;
KW identification; lactic acid bacterium; diarrhoea; pathogenic bacteria;
KW rotavirus; food composition; pharmaceutical composition.
XX
OS Bifidobacterium longum.
XX
PN EPI227152-A1.
XX
PD 31-JUL-2002.
XX
PF 30-JAN-2001; 2001EP-0102050.
XX
PR 30-JAN-2001; 2001EP-0102050.
XX
PA (NEST) SOC PROD NESTLE SA.
XX
DR WPI; 2002-668397/72.
XX
XX Novel polynucleotide comprising Bifidobacterium genome sequence useful
PT as a probe or primer for detecting and/or identifying Bifidobacterium
PT longum in a biological sample -
XX
PS Claim 3; SEQ ID 1043; 80pp; English.
XX
CC The present invention describes a polynucleotide (I) comprising a
CC sequence of a Bifidobacterium genome selected from the nucleotide
CC sequences given in ABQ81842 and ABQ81843, or a sequence exhibiting at
CC least 90% identity or which hybridises with the sequences given in
CC ABQ81842 and ABQ81843. Also described is a polynucleotide (II) encoding
CC a fusion protein, comprising a sequence selected from 1097 sequences
CC given in ABP65238 to ABP66354 ligated in frame to a polynucleotide
CC encoding a heterologous polypeptide. (I) has antidiarrheic and
CC antibacterial activities, and can be used as an inhibitor of Salmonella.
CC (I) (which is a probe) is useful for the detection and/or identification
CC of Bifidobacterium longum in a biological sample. A carrier containing
CC the lactic acid bacterium Bifidobacterium longum NCC2705 (NCIM 1-2618)
CC can be used for preventing and/or treating diarrhoea brought about by
CC pathogenic bacteria and/or rotavirus. The carrier is a food composition
CC selected from milk, yogurt, curd, cheese, fermented milks, milk based
CC fermented products, ice-creams, fermented cereal based products, milk
CC based powders, infant formula, pet food or a pharmaceutical composition
CC selected from tablets, liquid bacterial suspensions, dried oral
CC supplement, wet oral supplement, dry tube feeding or wet tube feeding.
CC (I) is useful in DNA arrays or chips to carry out analysis of the
CC expression of the Bifidobacterium gene. ABQ81844 to ABQ81850 represent
CC Bifidobacterium related nucleotide sequences given in the Sequence
CC Listing from the present invention but not mentioned further within the
CC specification.
CC N.B. The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office.
XX
SQ Sequence 388 AA;
Query Match 63.88; Score 37; DB 23; Length 388;
Best Local Similarity 60.08; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 6; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1 NTLKTPRVGG 10
: : : : : :
Db 2 HTPTPRMG 11
RESULT 11
AAU48931
ID AAU48931 standard; Protein: 92 AA.
XX
AC AAU48931;

XX 27-FEB-2002 (first entry)
DT
DE Propionibacterium acnes immunogenic protein #9827.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US12865.
XX
PR 21-APR-2000; 2000US-199047P.
XX
PR 02-JUN-2000; 2000US-208841P.
XX
PR 07-JUL-2000; 2000US-216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
XX
DR N-PSDB; AAS59543.
XX
XX Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris -
XX
PS Example 1; SEQ ID No 10126; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA).
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 92 AA;
Query Match 62.18; Score 36; DB 22; Length 92;
Best Local Similarity 87.58; Pred. No. 35;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TPRVGGXA 12
: : : : : :
Db 24 TPRVGGVA 31
RESULT 12
AAU93750
ID AAU93750 standard; Protein: 140 AA.
XX
AC AAU93750;

XX 06-NOV-2001 (first entry)
 DT Human polypeptide, SEQ ID NO: 3731.
 DE Human; full length cDNA; cDNA synthesis; oligo-capping.
 XX Homo sapiens.
 KW EP1130094-A2.
 OS 05-SEP-2001.
 PN 07-JUL-2000; 2000EP-0114089.
 XX 08-JUL-1999; 99JP-0194486.
 PR 11-JAN-2000; 2000JP-0118774.
 PR 02-MAY-2000; 2000JP-0183765.
 XX (HELI-) HELIX RES INST.
 PA Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
 PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
 XX WPI; 2001-524255/58.
 DR N-PSDB; AAK94702.
 XX 830 Primers useful for synthesizing full length cDNA clones and their
 PT use in genetic manipulation -
 XX Claim 8; SEQ ID NO 3731; 1380pp + sequence listing; English.
 XX The invention relates to primers for synthesizing full length cDNA
 CC clones. 830 cDNA molecules encoding a human protein have been
 CC isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
 CC molecules have been determined. Primers for synthesizing the full length
 CC cDNA are useful for clarifying the function of the protein encoded by
 CC the cDNA. The full length clones were obtained by construction of full
 CC length enriched cDNA libraries that were synthesised by the oligo-capping
 CC method. The primers enable the production of the full length cDNA easily
 CC without any special methods. The present sequence is a polypeptide
 CC encoded by a full length human cDNA of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in CD-ROM format directly from EPO.
 XX Sequence 140 AA;
 SQ

Query Match 62.1%; Score 36; DB 22; Length 140;
 Best Local Similarity 58.3%; Pred. No. 54;
 Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
 QY 1 NTLKTPRVGXA 12
 DB 36 STLPRPPGGDA 47
 RESULT 13
 ABB54460
 ID ABB54460 standard; Protein; 256 AA.
 XX AC ABB54460;
 XX 16-MAY-2002 (first entry)
 DT Lactococcus lactis protein ylfh.
 DE Lactococcus lactis ILL403.
 KW Biosynthesis; biodegradation; lactic bacterium; yogurt; cheese.
 XX Lactococcus lactis ILL403.
 OS FR2807446-A1.
 PN 12-OCT-2001.
 PD

XX 11-APR-2000; 2000FR-0004630.
 PF 11-APR-2000; 2000FR-0004630.
 PR (INRG) INRA INST NAT RECH AGRONOMIQUE.
 XX Bolotine A, Sorokine A, Renault P, Ehrlich SD;
 XX WPI; 2002-043418/06.
 DR New nucleotide sequence useful in the identification of Lactococcus
 XX lactis and related species -
 XX Claim 6; SEQ ID NO 1162; 2504pp; French.
 XX The present invention is related to a Lactococcus lactis nucleotide
 CC sequence (ABA90521) and related proteins (ABB53300-ABB55621). The
 CC nucleic acid sequence is useful in the detection and/or amplification of
 CC nucleic acid sequence, particularly to identify Lactococcus lactis or
 CC related species. The proteins of the invention are useful for the
 CC biosynthesis or biodegradation of a composition of interest. The
 CC invention helps research in lactic bacteria, particularly useful in the
 CC production of yogurt and cheese.
 CC Note: The sequence data for this patent is based on equivalent patent
 CC WO200177334 (published 18-OCT-2001) which is available in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 256 AA;
 SQ

Query Match 62.1%; Score 36; DB 23; Length 256;
 Best Local Similarity 87.5%; Pred. No. 1e+02;
 Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 NTLKTPRV 8
 DB 47 NTLKTPRV 54
 RESULT 14
 AAG06393
 ID AAG06393 standard; Protein; 319 AA.
 XX AC AAG06393;
 XX 17-OCT-2000 (first entry)
 DT Arabidopsis thaliana protein fragment SEQ ID NO: 3150.
 DE Protein identification; signal transduction pathway; metabolic pathway;
 KW hybridisation assay; genetic mapping; gene expression control; promoter;
 KW termination sequence.
 XX Arabidopsis thaliana.
 XX EP1033405-A2.
 PN 06-SEP-2000.
 PD 25-FEB-2000; 2000EP-0301439.
 PF 25-FEB-1999; 99US-0121825.
 XX 05-MAR-1999; 99US-0123180.
 PR 09-MAR-1999; 99US-0123548.
 PR 23-MAR-1999; 99US-0125788.
 PR 25-MAR-1999; 99US-0126264.
 PR 29-MAR-1999; 99US-0126785.
 PR 01-APR-1999; 99US-0127462.
 PR 06-APR-1999; 99US-0128234.
 PR 08-APR-1999; 99US-0128714.
 PR 16-APR-1999; 99US-0129845.
 PR 19-APR-1999; 99US-0130077.
 PR 21-APR-1999; 99US-0130449.

PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139859.
PR 23-JUN-1999; 99US-0140333.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143154.
PR 14-JUL-1999; 99US-0143542.
PR 15-JUL-1999; 99US-0143624.
PR 16-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.


```

PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 21-OCT-1999; 99US-0160880.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 62.1%; Score 36; DB 21; Length 319;
Best Local Similarity 77.8%; Pred. No. 1.3e-02;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 TLKTRVGG 10
Db 60 TLKTRVGG 68

RESULT 15
AAG06392
ID AAG06392 standard; Protein; 323 AA.
XX
AC AAG06392;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 3149.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 29-MAR-1999; 99US-0126264.
PR 01-APR-1999; 99US-0126785.
PR 06-APR-1999; 99US-0127462.
PR 08-APR-1999; 99US-0128234.
PR 16-APR-1999; 99US-0128714.
PR 19-APR-1999; 99US-0129845.
PR 21-APR-1999; 99US-0130077.
PR 23-APR-1999; 99US-0130449.
PR 28-APR-1999; 99US-0130510.
PR 30-APR-1999; 99US-0130891.
PR 30-APR-1999; 99US-0131449.
PR 04-MAY-1999; 99US-0132048.
PR 05-MAY-1999; 99US-0132407.
PR 05-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.

99US-0132486.
99US-0132487.
99US-0132863.
99US-0134256.
99US-0134218.
99US-0134219.
99US-0134221.
99US-0134370.
99US-0134768.
99US-0134941.
99US-0135124.
99US-0135353.
99US-0135629.
99US-0136021.
99US-0136392.
99US-0136782.
99US-0137222.
99US-0137528.
99US-0137502.
99US-0137724.
99US-0138094.
99US-0138540.
99US-0138847.
99US-0139119.
99US-0139452.
99US-0139453.
99US-0139492.
99US-0139454.
99US-0139455.
99US-0139456.
99US-0139457.
99US-0139458.
99US-0139459.
99US-0139460.
99US-0139461.
99US-0139462.
99US-0139463.
99US-0139750.
99US-0139763.
99US-0139817.
99US-0139899.
99US-0140353.
99US-0140354.
99US-0140695.
99US-0140823.
99US-0140991.
99US-0141287.
99US-0141842.
99US-0142154.
99US-0142055.
99US-0142390.
99US-0142803.
99US-0142920.
99US-0142977.
99US-0143542.
99US-0143624.
99US-0144005.
99US-0144085.
99US-0144086.
99US-0144325.
99US-0144331.
99US-0144332.
99US-0144333.
99US-0144334.
99US-0144335.
99US-0144352.
99US-0144632.
99US-0144884.
99US-0144814.
99US-0145086.
99US-0145088.
99US-0145085.
99US-0145087.

```

PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 28-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 16-AUG-1999; 99US-0148684.
PR 17-AUG-1999; 99US-0149368.
PR 18-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158212.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.

PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 62.1%; Score 36; DB 21; Length 323;
Best Local Similarity 77.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TLKTPRVGG 10
Db 64 TLKVPVGG 72

Search completed: August 28, 2003, 18:34:28
Job time : 38.0909 secs